Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the "Subclinical" pheochromocytoma

Archives of Surgery

Volumn 142, Issue 9, 2007, Pages 870-873

  Lee, James A ^a   Zarnegar, Rasa ^b   Shen, Wen T ^b   Kebebew, Electron ^b   Clark, Orlo H ^b   Duh, Quan Yang ^b,c  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CLOZAPINE; METADRENALIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADRENAL INCIDENTALOMA; ADRENALECTOMY; ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FALSE POSITIVE RESULT; HEART RATE; HUMAN; LAPAROSCOPIC SURGERY; PHEOCHROMOCYTOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYMPTOMATOLOGY; TUMOR VOLUME; URINALYSIS;

ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INCIDENTAL FINDINGS; LAPAROSCOPY; MALE; METANEPHRINE; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34548803141     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.142.9.870     Document Type: Article

References (17)

1. Glazer HS, Weyman PJ, Sagel SS, Levitt RG, McClennan BL. Nonfunctioning adrenal masses. AJR Am J Roentgenol. 1982;139(1):81-85.
2. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003;138(5):424-429.
3. Mantero F, Terzolo M, Arnaldi G, et al; Study Group on Adrenal Tumors of the Italian Society of Endocrinology. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab. 2000;85(2):637-644.
4. Linos D. Clinically inapparent adrenal mass (incidentaloma or adrenaloma). In: Clark OH, Duh QY, Kebebew E, eds. Textbook of Endocrine Surgery. 2nd ed. San Francisco, CA: Elsevier; 2005:586-594.
5. Kudva YC, Sawka AM, Young WF Jr. Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab. 2003;88(10):4533-4539.
6. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427-1434.
7. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997;47(4-6):279-283.
8. Kebebew E, Siperstein AE, Clark OH, Duh QY. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch Surg. 2002;137(8):948-953.
9. Terzolo M, Ali A, Osella G, Mazza E; Gruppo Piemontese Incidentalomi Surrenalici. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses: a retrospective study from 1989 to 1994. Arch Surg. 1997;132(8):914-919.
10. Harding JL, Yeh MW, Robinson BG, Delbridge LW, Sidhu SB. Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust. 2005;182(12):637-640.
11. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88(6):2656-2666.
12. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adrenal tumors. Surgery. 1991;110(6):1014-1021.
13. Bernini GP, Vivaldi MS, Argenio GF, Moretti A, Sgrò M, Salvetti A. Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis. J Endocrinol Invest. 1997;20(2):65-71.
14. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87(11):4872-4878.
15. Krentz AJ, Mikhail S, Cantrell P, Hill GM. Drug points: pseudophaeochromocytoma syndrome associated with clozapine. BMJ. 2001;322(7296):1213.
16. Swedberg K, Bristow MR, Cohn JN, et al; Moxonidine Safety and Efficacy (MOXSE) Investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002; 105(15):1797-1803.
17. Veith RC, Lewis N, Linares OA, et al. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 1994;51(5):411-422.